Harnessing the power of antisense technology for combination chemotherapy

Journal of the National Cancer Institute

Volumn 89, Issue 2, 1997, Pages 107-108

  Narayanan, R ^a  

^a HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA;

BIOTECHNOLOGY; CANCER CHEMOTHERAPY; CHROMOSOME TRANSLOCATION; EDITORIAL; LEUKEMIA CELL; PHILADELPHIA 1 CHROMOSOME;

EID: 0031033197     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.2.107     Document Type: Editorial

References (21)

1. Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M. Chronic myelogenous leukemia: a concise update. Blood 1993;82:691-703.
2. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TG. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death [published erratum appears in Blood 1994;83:3835]. Blood 1994;83:1179-87.
3. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 1994;83: 2038-44.
4. Foti A, Ahuja HG, Allen SL, Koduru P, Schuster MW, Schulman P, et al. Correlation between molecular and clinical events in the evolution of chronic myelocytic leukemia to blast crisis. Blood 1991;77:2441-4.
5. Stein CA, Cheng YC. Antisense oligonucleotides as therapeutic agents—is the bullet really magical? Science 1993;261:1004-12.
6. Stein CA, Narayanan R. Antisense oligodeoxynucleotides. Curr Opin Oncol 1994;6:587-94.
7. Sharma HW, Narayanan R. The therapeutic potential of antisense oligonucleotides. Bioessays 1995;17:1055-63.
8. Narayanan R, Akhtar S. Antisense therapy of cancer. Curr Opin Oncol 1996;8:509-15.
9. Szczylik C, Skorski T, Nicolaides NC, Manzella L, Malaguarnera L, Venturelli D, et al. Selective inhibition of leukemia cell proliferation by BCRABL antisense oligodeoxynucleotides. Science 1991;253:562-5.
10. de Fabritiis P, Amadori S, Calabretta B, Mandelli F. Elimination of clonogenic Philadelphia chromosome-positive cells using BCR-ABL antisense oligodeoxynucleotides. Bone Marrow Transplant 1993;12:261-5.
11. Kirkland MA, O'Brien SG, McDonald C, Davidson RJ, Cross NC, Goldman JM. BCR-ABL antisense purging in chronic myeloid leukaemia [letter]. Lancet 1993;342:614.
12. Skorski T, Nieborowska-Skorska M, Barletta C, Malaguarnera L, Szcyzlik C, Chen ST, et al. Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamide. J Clin Invest 1993;92:194-202.
13. Smetsers TF, Skorski T, van de Locht LT, Wessels HM, Pennings AH, de Witte T, et al. Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173. Leukemia 1993;8: 129-40.
14. Skorski T, Nieborowska-Skorska M, Nicodaides N, Szczylik C, Iversen P, Iozzo RV, et al. Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotides. Proc Natl Acad Sci USA 1994;91:4504-8.
15. Mahon FX, Ripoche J, Pigeonnier V, Jazwiec B, Pigneux A, Moreau JF, et al. Inhibition of chronic myelogenous leukemia cells harboring a BCRABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction. Exp Hematol 1995;23:1606-11.
16. Skorski T, Nieborowska-Skorska M, Wlodarski P, Perrotti D, Hoser G, Kawiak J, et al. Treatment of Philadelphia1 leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides. J Natl Cancer Inst 1997;89:124-33.
17. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-62.
18. Bergan R, Connell Y, Fahmy B, Kyle E, Neckers L. Aptameric inhibition of p210bcr-abl tyrosine kinase autophosphorylation by oligodeoxynucleotides of defined sequence and backbone structure. Nucleic Acids Res 1994; 22:2150-4.
19. O'Brien SG, Kirkland MA, Melo JV, Rao MH, Davidson RJ, McDonald C, et al. Antisense BCR-ABL oligomers cause non-specific inhibition of chronic myeloid leukemia cell lines. Leukemia 1994;8:2156-62.
20. Smetsers TF, van de Locht LT, Pennings AH, Wessels HM, de Witte TM, Mensink EJ. Phosphorothioate BCR-ABL antisense oligonucleotides induce cell death, but fail to reduce cellular bcr-abl protein levels. Leukemia 1995;9:118-30.
21. Vaerman JL, Lammineur C, Moreau P, Lewalle P, Deldime F, Blumenfeld M, et al. BCR-ABL antisense oligodeoxyribonucleotides suppress the growth of leukemic and normal hematopoietic cells by a sequence-specific but nonantisense mechanism. Blood 1995;86:3891-6.